A new era of cardiac nephroprotection in patients with type 2 diabetes mellitus: the role of Finerenone
The main factor in modern healthcare is to increase the length and quality of life of patients, especially with socially significant diseases, such as type 2 diabetes mellitus (T2DM) and its dangerous complication — chronic kidney disease (CKD), associated with a high rate of cardiovascular diseases...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2025-01-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/13222 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850140843336269824 |
|---|---|
| author | I. S. Khalimov E. A. Polyakova Yu. A. Shutova |
| author_facet | I. S. Khalimov E. A. Polyakova Yu. A. Shutova |
| author_sort | I. S. Khalimov |
| collection | DOAJ |
| description | The main factor in modern healthcare is to increase the length and quality of life of patients, especially with socially significant diseases, such as type 2 diabetes mellitus (T2DM) and its dangerous complication — chronic kidney disease (CKD), associated with a high rate of cardiovascular diseases (CVD), end-stage renal disease and mortality. Effective management of cardiorenal risks in addition with blockers of the renin-angiotensin-aldosterone system and sodium-glucose cotransporter type 2 inhibitors was replenished in 2023 with a new non-steroidal selective mineralocorticoid receptor antagonist — Finerenone. This unique and one-of-a-kind drug improves the control of cellular processes, fibrosis in the kidneys and myocardial remodeling. This review presents the main studies on the mechanism of action of Finerenone, assessment of its effectiveness and safety, and its effect on the risk of developing cardiorenal risk in patients with T2DM. Finerenone is one-of-a-kind drug who has no alternatives to improve a control of cellular processes, a fibrosis in the kidneys and a myocardial remodeling. In this review we presented Finerenone effects on an eGFR slope as a main kidney function feature, and proposed practice points on safe initiation of the three cardiorenal «pillars» in patients with T2DM in accordance with the current clinical guidelines. |
| format | Article |
| id | doaj-art-3c9a80593c8a493faf3ac7e1e49033ce |
| institution | OA Journals |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-3c9a80593c8a493faf3ac7e1e49033ce2025-08-20T02:29:41ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782025-01-0127662062810.14341/DM1322211133A new era of cardiac nephroprotection in patients with type 2 diabetes mellitus: the role of FinerenoneI. S. Khalimov0E. A. Polyakova1Yu. A. Shutova2Pavlov First Saint Petersburg State Medical UniversityPavlov First Saint Petersburg State Medical UniversityJSC BayerThe main factor in modern healthcare is to increase the length and quality of life of patients, especially with socially significant diseases, such as type 2 diabetes mellitus (T2DM) and its dangerous complication — chronic kidney disease (CKD), associated with a high rate of cardiovascular diseases (CVD), end-stage renal disease and mortality. Effective management of cardiorenal risks in addition with blockers of the renin-angiotensin-aldosterone system and sodium-glucose cotransporter type 2 inhibitors was replenished in 2023 with a new non-steroidal selective mineralocorticoid receptor antagonist — Finerenone. This unique and one-of-a-kind drug improves the control of cellular processes, fibrosis in the kidneys and myocardial remodeling. This review presents the main studies on the mechanism of action of Finerenone, assessment of its effectiveness and safety, and its effect on the risk of developing cardiorenal risk in patients with T2DM. Finerenone is one-of-a-kind drug who has no alternatives to improve a control of cellular processes, a fibrosis in the kidneys and a myocardial remodeling. In this review we presented Finerenone effects on an eGFR slope as a main kidney function feature, and proposed practice points on safe initiation of the three cardiorenal «pillars» in patients with T2DM in accordance with the current clinical guidelines.https://www.dia-endojournals.ru/jour/article/view/13222diabetes mellitusсhronic kidney diseaseegfr slopefinerenone |
| spellingShingle | I. S. Khalimov E. A. Polyakova Yu. A. Shutova A new era of cardiac nephroprotection in patients with type 2 diabetes mellitus: the role of Finerenone Сахарный диабет diabetes mellitus сhronic kidney disease egfr slope finerenone |
| title | A new era of cardiac nephroprotection in patients with type 2 diabetes mellitus: the role of Finerenone |
| title_full | A new era of cardiac nephroprotection in patients with type 2 diabetes mellitus: the role of Finerenone |
| title_fullStr | A new era of cardiac nephroprotection in patients with type 2 diabetes mellitus: the role of Finerenone |
| title_full_unstemmed | A new era of cardiac nephroprotection in patients with type 2 diabetes mellitus: the role of Finerenone |
| title_short | A new era of cardiac nephroprotection in patients with type 2 diabetes mellitus: the role of Finerenone |
| title_sort | new era of cardiac nephroprotection in patients with type 2 diabetes mellitus the role of finerenone |
| topic | diabetes mellitus сhronic kidney disease egfr slope finerenone |
| url | https://www.dia-endojournals.ru/jour/article/view/13222 |
| work_keys_str_mv | AT iskhalimov aneweraofcardiacnephroprotectioninpatientswithtype2diabetesmellitustheroleoffinerenone AT eapolyakova aneweraofcardiacnephroprotectioninpatientswithtype2diabetesmellitustheroleoffinerenone AT yuashutova aneweraofcardiacnephroprotectioninpatientswithtype2diabetesmellitustheroleoffinerenone AT iskhalimov neweraofcardiacnephroprotectioninpatientswithtype2diabetesmellitustheroleoffinerenone AT eapolyakova neweraofcardiacnephroprotectioninpatientswithtype2diabetesmellitustheroleoffinerenone AT yuashutova neweraofcardiacnephroprotectioninpatientswithtype2diabetesmellitustheroleoffinerenone |